Home: PCU
5|2003: Joseph A Smith Jr, MD: Select publications
Select publications
Publications discussed by Dr Smith
The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. Br J Urol 1997;79(2):235-46. Abstract
Bolla M et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300. Abstract
Bolla M et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002;360(9327):103-6. Abstract
Messing EM et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-8. Abstract
Biochemical (PSA) recurrence
Carroll P. Rising PSA after a radical treatment. Eur Urol 2001;40 (Suppl 2):9-16. Abstract
Djavan B et al. PSA progression following radical prostatectomy and radiation therapy: New standards in the new Millennium. Eur Urol 2003;43(1):12-27. Abstract
Dreicer R. Controversies in the systemic management of patients with evidence of biochemical failure following radical prostatectomy. Cancer Treat Rev 2002;28(4):189-94. Abstract
Grossfeld GD et al. Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy. Urology 2001;58(2 Suppl 1):56-64. Abstract
Grossfeld GD et al. Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy. Urology 2002;60(3 Suppl 1):57-62; discussion 62-3. Abstract
Moul JW. Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy. Mol Urol 2000;4(3):267-71;discussion 273. Abstract
Swindle PW et al. Markers and meaning of primary treatment failure. Urol Clin North Am 2003;30(2):377-401. Abstract
Sylvester J et al. The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: A survey of practice patterns of urologists and radiation oncologists in the United States. Urology 2001;58(2 Suppl 1):65-70. Abstract
Intermittent versus continuous androgen suppression
De La Taille A et al. Intermittent androgen suppression in patients with prostate cancer. BJU Int 2003;91(1):18-22. Abstract
Gaston KE, Ornstein DK. Pharmacotherapy for biochemical recurrences after therapy for localised prostate cancer. Expert Opin Pharmacother 2002;3(6):657-69. Abstract
Goldenberg SL et al. Clinical experience with intermittent androgen suppression in prostate cancer: Minimum of 3 years' follow-up. Mol Urol 1999;3(3):287-292. Abstract
Grossfeld GD et al. Intermittent androgen deprivation: Update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology 2001;58(2):240-5. Abstract
Hurtado-Coll A et al. Intermittent androgen suppression in prostate cancer: The Canadian experience. Urology 2002;60(3 Suppl 1):52-6;discussion 56. Abstract
Irani J. Intermittent androgen suppression in the management of prostate cancer: A phase II comparative study. Prostate Cancer Prostatic Dis 2000;3(S1):S20. No abstract available.
Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer 2000;88(12 Suppl):3009-14. Abstract
Leibowitz RL, Tucker SJ. Treatment of localized prostate cancer with intermittent triple androgen blockade: Preliminary results in 110 consecutive patients. Oncologist 2001;6(2):177-82. Abstract
Malone S et al. Mature phase II study of intermittent androgen suppression therapy (IAS) in prostate cancer (PC): Efficacy and long-term side effect profile. Int J Radiat Oncol Biol Phys 2003;57(2 Suppl):S174-5. No abstract available.
Pether M et al. Intermittent androgen suppression in prostate cancer: An update of the Vancouver experience. Can J Urol 2003;10(2):1809-14. Abstract
Prapotnich D et al. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 2003;43(3):233-40. Abstract
|
